Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

By H. Ghofrani, A. D’Armini, F. Grimminger, M. Hoeper, P. Jansa, Nick H. Kim, E. Mayer, G. Simonneau, M. Wilkins, A. Fritsch and 3 more. New England Journal of Medicine, 2013

1,261 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/ae5f06bf448236bef91d252053bc368eeb94d266

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Pulmonary and Respiratory Medicine

N. Galiè

Citations in the corpus

Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, background): “In patients with inoperable CTEPH or persistent pulmonary hypertension after pulmonary thromboendarterectomy, there is new evidence from a randomized trial that pulmonary vasodilator therapy may be of benefit.(163) For these reasons, we no longer identify central disease as a selection factor for th”
Riociguat for the treatment of pulmonary arterial hypertension. (2013, background): “Start of new treatment for pulmonary hypertension 5 (4) 1 (<1) 1 (2)”
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, methodology): “Based on available data, medical treatment of CTEPH with targeted therapy is now justified for technically inoperable patients,(469,470) as well as for patients with PH persisting after PEA.(469) To date, the only drug approved for inoperable CTEPH or persistent/recurrent PH after PEA is riociguat, ”
ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, background): “001; secondary endpoint); the time to clinical worsening remained unchanged.(411)”
[2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, neutral): “001; secondary endpoint); the time to clinical worsening remained unchanged.(411)”